Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Eurofins Scientific SE (ESF.VI)
Luxembourg City, LU, LU
Eurofins Scientific SE, together with its subsidiaries, offers a comprehensive suite of analytical and laboratory testing solutions worldwide. The company utilizes an extensive portfolio of approximately 130,000 analytical methodologies to thoroughly assess the safety, identity, composition, authenticity, origin, traceability, and purity of a wide variety of products. Its diverse services encompass numerous key sectors. In agroscience, offerings include biological assessments, product chemistry, regulatory consultancy, and seed services, complementing general agro testing. Environmental testing addresses crucial analyses of water, air, soil, and waste. For food and feed, services range from allergen and GMO detection to grain and meat quality evaluations, nanomaterial identification, pesticide screening, and residual DNA analysis. The consumer product testing division ensures compliance through audits, inspections, certifications, approvals, and training, even extending to digital media and cybersecurity for various industries, alongside specialized services for cosmetics and personal care. The company is also deeply involved in biopharma and clinical diagnostics. Advanced testing capabilities include detection of persistent organic pollutants (POPs), dioxins, various organic contaminants, pesticides, mycotoxins, allergens, pathogens, and vitamins, as well as genetic modification analyses. Assurance services provide product inspection, auditing, certification, training, and consultation across food, consumer products, healthcare, and cosmetics. Additionally, Eurofins offers expertise in forensic science, genomics, maritime assessments, materials and engineering, REACH compliance, and technology services. Eurofins Scientific SE was established in 1987 and is headquartered in Luxembourg City, Luxembourg.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.42% | -1.18% | +7.21% | -8.83% | +5.50% | -0.22% | +6.69% | +0.26% | -29.61% | -5.13% | -5.13% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Medical - Diagnostics & Research: +7.9%+5.0% Q4'25: +11.5% (vs Q4'23)
-
EPS growth Medical - Diagnostics & Research: +30.8%+22.1% Q4'25: +53.8% (vs Q4'23)
-
FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%+7.2% Q4'25: +6.8% (vs Q4'23)
-
EBIT margin Medical - Diagnostics & Research: +9.6%+11.2% ★ Q4'25: +11.4% (vs Q4'23)
-
ROIC Medical - Diagnostics & Research: +5.2%+7.2% ★ Q4'25: +15.0% (vs Q4'23)
-
Share dilution Medical - Diagnostics & Research: 0.0%-3.9% ★ Q4'25: -5.0% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×3.75× Q4'25: 1.96× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 11 Rev. Ana. 1 EPS Ana. |
Dec 2027 12 Rev. Ana. 1 EPS Ana. |
Dec 2028 6 Rev. Ana. 1 EPS Ana. |
Dec 2029 11 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.95B
est: 1.93B (+0.8%)
|
2.54B
est: 2.54B (0.0%)
|
2.97B
est: 2.97B (+0.1%)
|
3.78B
est: 3.79B (-0.3%)
|
4.56B
est: 4.53B (+0.7%)
|
5.44B
est: 5.40B (+0.7%)
|
6.72B
est: 6.56B (+2.3%)
|
6.71B
est: 6.74B (-0.4%)
|
6.51B
est: 6.52B (-0.1%)
|
6.95B
est: 6.96B (-0.1%)
|
7.30B
est: 7.31B (-0.2%)
|
7.61B
7.44B – 7.74B
+4.2% YoY
|
8.04B
7.53B – 8.40B
+5.7% YoY
|
8.62B
8.24B – 8.89B
+7.2% YoY
|
9.42B
9.01B – 9.71B
+9.3% YoY
|
| EBITDA |
319.96M
est: 426.47M (-25.0%)
|
477.96M
est: 559.14M (-14.5%)
|
518.14M
est: 654.18M (-20.8%)
|
654.71M
est: 835.66M (-21.7%)
|
859.60M
est: 998.66M (-13.9%)
|
1.28B
est: 1.19B (+7.8%)
|
1.75B
est: 1.45B (+21.1%)
|
1.47B
est: 1.49B (-0.8%)
|
1.22B
est: 1.44B (-15.4%)
|
1.38B
est: 1.48B (-6.8%)
|
1.45B
est: 1.56B (-6.9%)
|
1.62B
1.59B – 1.65B
+4.2% YoY
|
1.71B
1.60B – 1.79B
+5.7% YoY
|
1.84B
1.76B – 1.89B
+7.2% YoY
|
2.01B
1.92B – 2.07B
+9.3% YoY
|
| EBIT |
185.85M
est: 248.09M (-25.1%)
|
311.67M
est: 325.26M (-4.2%)
|
305.13M
est: 380.54M (-19.8%)
|
353.16M
est: 486.11M (-27.4%)
|
369.00M
est: 580.94M (-36.5%)
|
788.70M
est: 692.36M (+13.9%)
|
1.23B
est: 841.61M (+45.8%)
|
867.40M
est: 864.30M (+0.4%)
|
552.70M
est: 836.35M (-33.9%)
|
695.30M
est: 846.79M (-17.9%)
|
819.00M
est: 889.08M (-7.9%)
|
926.25M
905.73M – 941.49M
+4.2% YoY
|
978.71M
915.94M – 1.02B
+5.7% YoY
|
1.05B
1.00B – 1.08B
+7.2% YoY
|
1.15B
1.10B – 1.18B
+9.3% YoY
|
| Net Income |
87.32M
est: 153.32M (-43.0%)
|
174.00M
est: 207.12M (-16.0%)
|
216.77M
est: 236.30M (-8.3%)
|
223.94M
est: 296.16M (-24.4%)
|
195.20M
est: 328.50M (-40.6%)
|
539.40M
est: 553.56M (-2.6%)
|
782.60M
est: 902.57M (-13.3%)
|
610.20M
est: 692.34M (-11.9%)
|
310.20M
est: 493.14M (-37.1%)
|
406.40M
est: 568.10M (-28.5%)
|
475.00M
est: 665.63M (-28.6%)
|
703.23M
663.20M – 731.40M
+5.6% YoY
|
819.80M
773.14M – 852.65M
+16.6% YoY
|
956.59M
902.15M – 994.92M
+16.7% YoY
|
1.03B
968.23M – 1.07B
+7.3% YoY
|
| SGA |
—
est: 12.84M (-100.0%)
|
—
est: 16.83M (-100.0%)
|
—
est: 19.69M (-100.0%)
|
—
est: 25.15M (-100.0%)
|
52.50M
est: 30.06M (+74.7%)
|
38.20M
est: 35.82M (+6.6%)
|
60.30M
est: 43.54M (+38.5%)
|
39.40M
est: 44.72M (-11.9%)
|
73.60M
est: 43.27M (+70.1%)
|
—
est: 36.39M (-100.0%)
|
—
est: 38.21M (-100.0%)
|
39.81M
38.93M – 40.46M
+4.2% YoY
|
42.06M
39.37M – 43.93M
+5.7% YoY
|
45.08M
43.10M – 46.47M
+7.2% YoY
|
49.27M
47.12M – 50.79M
+9.3% YoY
|
| EPS |
0.57
est: 0.79 (-27.7%)
|
0.87
est: 1.06 (-18.3%)
|
1.05
est: 1.21 (-13.6%)
|
1.27
est: 1.52 (-16.6%)
|
1.10
est: 1.69 (-34.9%)
|
2.90
est: 2.85 (+1.9%)
|
4.09
est: 4.64 (-11.9%)
|
3.17
est: 3.56 (-10.9%)
|
1.61
est: 2.54 (-36.5%)
|
2.13
est: 3.04 (-29.9%)
|
2.64
est: 3.56 (-25.8%)
|
3.76
3.55 – 3.91
+5.6% YoY
|
4.38
4.13 – 4.56
+16.6% YoY
|
5.12
4.82 – 5.32
+16.7% YoY
|
5.49
5.18 – 5.71
+7.3% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-28 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-27 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-26 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-25 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-22 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-21 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-20 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-19 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-18 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-15 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-14 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-13 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-12 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-11 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-08 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-07 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-06 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-05 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-04 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-30 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-29 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-28 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-27 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-24 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-23 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-22 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-21 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-20 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-17 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-16 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Gilles G. Martin | Chairman of the Board & Chief Executive Officer | 3M | — |
| Valerie Hanote | Executive Director | 462.0K | female |
| Francois Vigneau | Senior Vice President of Food & Feed Testing - Western Europe | — | male |
| Gabriel Julia | Senior Vice President of Clinical Diagnostics Europe | — | male |
| Joachim Reichelt | Senior Vice President of Food & Feed Testing Europe | — | male |
| Laurent Lebras | Group Administration & Chief Financial Officer | — | male |
| Timothy S. Oostdyk | Executive Vice President of BioPharma, Genomics & Agrosciences Services North America | — | — |
| Bernard Wang | Head of Investor Relations | — | male |
| Yvoine Remy | Senior Vice President of Environment Testing Europe | — | female |
| David W. Bryant | Senior Vice President of Strategic Business Development North America | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ESF.VI
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
